Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates

Oragenics, Inc. has submitted its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. The filing provides a comprehensive overview of the company’s financial performance, operational highlights, and strategic developments over the past year. The report is publicly available through the U.S. Securities and Exchange Commission (SEC) website.

The document includes detailed financial statements, management’s discussion and analysis of financial conditions, and disclosures regarding risks and uncertainties facing the company. Oragenics operates in the biotechnology sector with a focus on developing treatments for infectious diseases and other medical needs. The filing also outlines updates on ongoing research initiatives, intellectual property matters, and future plans for product development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 17, 2026

Author

GOAI